☆ 4.7 Editorial Material

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Get Full Text
Add to Collection

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 28, Issue 8, Pages 1044-1046

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2022.03.030

Keywords

Antivirals; COVID-19; Drug safety; Drug-drug interactions; Nirmatrelvir; Ritonavir; Pharmacokinetic boosters

Categories

Infectious Diseases Microbiology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.